A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain

Summary

The main purpose of this study is to assess whether LY3857210 is safe and efficacious in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.

Timeline

Start

2022-12-08

Primary completion

2023-06-09

Completion

2023-06-15

Outcome

Missed primary endpoint

registry analysis (superiority test); 45 mg LY3857210 vs Placebo; Posterior Mean Difference 0.39 (95% CI -0.22 to 1.00) NCT05630196 ↗

registry MEAN 45 mg LY3857210: -1.24 (-1.59 to -0.89) score on a scale NCT05630196 ↗

registry MEAN Placebo: -1.63 (-2.14 to -1.13) score on a scale NCT05630196 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3857210	Unknown	45 mg	Oral

Indications